Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | ACP3 | P15309 | 13/20 | 0.54 |
| ▸ | PGK1 | P00558 | 3/20 | 0.48 |
| ▸ | PGK2 | P07205 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9301497 | 0.86 | SRC (0.75) | SRCACP3PGK1PGK2CA12 | |
| SCHEMBL9450680 | 0.82 | SRC (0.70) | SRCACP3PGK1PGK2 | |
| SCHEMBL31107106 | 0.81 | SRC (0.67) | SRCACP3 | |
| SCHEMBL3385301 | 0.81 | SRC (0.67) | SRCACP3 | |
| SCHEMBL8855634 | 0.81 | SRC (0.67) | SRCACP3PGK1PGK2CA12 | |
| SCHEMBL27465781 | 0.80 | SRC (0.64) | SRCACP3PGK1PGK2 | |
| SCHEMBL2171583 | 0.79 | SRC (0.65) | SRCACP3PGK1PGK2 | |
| SCHEMBL232244 | 0.79 | ACP3 (0.79) | SRCACP3PGK1PGK2 | |
| Hydrochloric Acid SCHEMBL1133241 | 0.77 | ACP3 (0.76) | SRCACP3 | |
| Alpha Hydroxy Benzylphosphonate SCHEMBL5744616 | 0.77 | PGK1 (0.71) | SRCACP3PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0857227-B1 | SHORT DURATION HOT SEAL FOR ANODISED METAL SURFACES | HENKEL KGAA (DE) | 2000-01-26 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3348269-B1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | UNIV TSINGHUA (CN) | 2023-11-15 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| US-5156824-A | Extracting metals especially uranium, actinides and lanthanides | COMPAGNIE FRANCAISE DE MOKTA (FR) | 1992-10-20 | — | — | US | disclosed |
| US-4774262-A | CROSSLINKED, BINDING, ESTERIFICATION RECOVERING METALS | MINEMET RECHERCHE (FR) | 1988-09-27 | — | — | US | disclosed |
| EP-0210571-A1 | Phosphonopyridines and their 1,4-dihydroderivatives | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1987-02-04 | — | — | EP | disclosed |
| US-4579720-A | USING HYDROXYMETHANE DIPHOSPHONIC ACID | PLAINS CHEMICAL DEVELOPMENT CO. (US) | 1986-04-01 | — | — | US | disclosed |
| US-4440646-A | HYDROXY OR HALOALKANEPHOSPHONATES | PLAINS CHEMICAL DEVELOPMENT CO. (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0015370-B1 | DIPHOSPHONATE OR PHOSPHATE-PHOSPHONATE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYMPHAR S.A. (CH) | 1983-01-12 | — | — | EP | disclosed |
| US-4188234-A | STABILIZATION OF VINYL POLYMERS, POLYPHOSPHONIC ACID CHELATING AGENT, PROTECTIVE COATINGS | PLAINS CHEMICAL DEVELOPMENT CO. (US) | 1980-02-12 | — | — | US | disclosed |
| US-4150024-A | Reaction products of epsilon-caprolactam with vicinal hydroxyalkylamines and alkoxylation products thereof | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4116990-A | OF NON-ALKALI METAL IONS WITH PHOSPHORUS CHELATING COMPOUND | PLAINS CHEMICAL DEVELOPMENT CO. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4020091-A | TIN SALTS OF POLYPHOSPHONIC ACIDS | PLAINS CHEMICAL DEVELOPMENT CO. (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | GGPS1, HMGCR, COASY | SRC 1894/4885ACP3 662/4885PGK1 78/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | SRC 1894/4885ACP3 677/4885PGK1 74/4885 |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | SRC 1887/4885ACP3 668/4885PGK1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.